As Pfizer and BioNTech tout the effectiveness of their bivalent booster against Omicron variants such as BA.4 and BA.5, more Covid-19 variants have been creeping up on the general public. Now the partners are lifting the cover on new data showing its effectiveness against the newer variants of the virus.
On Friday, Pfizer and BioNTech reported new results analyzing the immune response induced by the bivalent Covid-19 vaccine against the newer “sublineages” including BA.4.6, BA.2.75.2, BQ.1.1 and XBB.1, with Pfizer and BioNTech stating that the vaccine “elicits a greater increase in neutralizing antibody titers” than the original vaccine against these sublineages and providing overall protection.
The data, which were posted to bioRxiv, shows that after a dose of the BA.4/BA.5 bivalent vaccine, the neutralizing antibodies against BA.4.6 increased 11.1-fold, with BA.2.75.2, BQ1.1 and XBB.1 seeing increases of 6.7, 8.7 and 4.8 respectively. The protection with the…
Click here to view original post